Catalyst defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for its high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were “in line” with similar products in the industry.

Sanders had earlier this month written to the Florida-based drugmaker asking it to justify its $375,000-per-year price for Firdapse, a medication that for years has been available for free.